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Abstract: Rare inherited coagulation disorders (RICDs) are congenital deficiencies of the plasma
proteins that are involved in blood coagulation, which generally lead to lifelong bleeding
manifestations. These diseases are generally qualitative and/or quantitative defects that are
associated with monoallelic or biallelic mutations in the relevant gene. Among RICDs, factor V
(FV) deficiency is one of the least characterized at the molecular level. Here, we investigated four
unrelated patients with reduced plasma FV levels (three severe, one mild), which were associated
with a moderately severe bleeding tendency. Sequence analysis of the FV gene identified seven
different variants, five hitherto unknown (p.D1669G, c.5789-11C>A, c.5789-12C>A, c.5789-5T>G,
and c.6528G>C), and two previously reported (c.158+1G>A and c.5789G>A). The possible pathogenic
role of the newly identified missense variant was studied by in silico approaches. The remaining
six genetic defects (all putative splicing mutations) were investigated for their possible effects on
pre-mRNA splicing by transient transfection experiments in HeLa cells with plasmids expressing
appropriate hybrid minigenes. The preparation of minigene constructs was instrumental to
demonstrate that the two adjacent variants c.5789-11C>A and c.5789-12C>A are indeed present
in cis in the analyzed FV-deficient patient (thus leading to the c.5789-11_12CC>AA mutation).
Ex vivo experiments demonstrated that each variant causes either a skipping of the relevant exon
or the activation of cryptic splice sites (exonic or intronic), eventually leading to the introduction of
a premature termination codon.
Keywords: coagulation factor V; factor V deficiency; splicing mutations; minigene expression
experiments; mutational spectrum
1. Introduction
Factor V (FV), which is also known as proaccelerin or labile factor, is a 330-kDa multi-domain
(A1–A2–B–A3–C1–C2) procofactor of the coagulation cascade showing no intrinsic coagulant activity
until its conversion to activated FV (FVa) [1–3]. FV activation occurs by a limited proteolysis, which is
exerted either by thrombin or activated factor X (FXa) at specific arginine residues, i.e., p.Arg709,
p.Arg1018, and p.Arg1545; this results in the removal of the large B domain [1–3]. Once activated, FVa,
together with FXa, participates in the formation of the prothrombinase complex, which is responsible
for the generation of thrombin [1–3]. FV also shows an anticoagulant activity, by acting (together with
protein S) in the activated protein C-mediated inactivation of activated factor VIII [4].
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FV deficiency (Online Mendelian Inheritance in Man #227400) is an inherited coagulation disorder
that was originally described by Owren in 1947 as a hemorrhagic diathesis due to the absence
of a previously unknown coagulation factor [5]. A few years later, the modality of transmission
(autosomal recessive) became clear [6], whereas the isolation and molecular characterization of
homogeneous FV was achieved only in 1979 [7]. FV deficiency is rare, with an estimated prevalence
of one per million in the general population, but in countries where consanguineous marriages
are frequent, the disorder can occur up to 10 times more frequently [8,9]. The disease can be
classified as either type-I deficiency—which is characterized by FV antigen levels that can be
mildly reduced, low, or even unmeasurable (quantitative defect)—or type-II deficiency, showing
normal or slightly-decreased antigen levels associated with reduced coagulant activity (qualitative
defect) [10]. Altered levels of the coagulation factor are responsible for clinical manifestations going
from life-threatening bleeding episodes (mostly in the gastrointestinal tract and the central nervous
system) to less severe symptoms, including epistaxis, menorrhagia, easy bruising, hemarthroses,
and hematomas [10,11].
FV quantitative defects are associated with monoallelic and biallelic mutations in the FV gene
(F5), which consists of 25 exons, covers a genomic region of 74.6 kb, and is located on chromosome
1q24.2 (Human genome assembly GRCh37/hg19; UCSC Genome Browser, http://genome.ucsc.edu/)
(access on 20 December 2018). According to the publicly available version of the Human Gene
Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php) (access on 20 December 2018),
a total of 134 genetic defects have been described as associated with FV deficiency so far; among
them, 14 mutations (10.4%) affecting splicing have been identified, even though these have not been
functionally investigated in all of the cases [12–24].
In this work, we report the full molecular and functional characterization of four patients affected
by FV deficiency. The study was carried out through an initial sequencing of the F5 coding sequence,
and by a subsequent combination of in silico analyses and ex vivo expression experiments. In addition,
a detailed review of the literature with a specific focus on F5 splicing defects, as well as data mining
in publicly available mutation/variation databases, revealed that a great proportion of such variants
are indeed due to misinterpreted missense/synonymous substitutions falling in the exonic regions of
splicing sites.
2. Results
2.1. Clinical Details of the Patients
Four unrelated patients (P1–P4) with congenital FV deficiency were included in this study.
They were enrolled among consecutive patients referring to our collaborating centers on the basis of
a coagulatory screening revealing a FV coagulant activity (FV:C) < 5% in three cases, and FV:C = 56%
in the remaining one. The main clinical features of these patients are summarized in Table 1.
Table 1. Clinical data of the analyzed factor V (FV)-deficient patients.
Patient Origin Present Age(Years) Sex FV:C (%) FV:Ag (%)
Main Hemorrhagic
Manifestations/Challenges
P1 Italy 29 F 3 2
Ecchymoses;
Surgery for cysts removal on knee, resulting in
post-surgery bleeding and consequent anemia
(no treatment used)
P2 Italy 52 F 55 53
Two pregnancies, both with premature
delivery, and in one case post-delivery
bleeding (two days after the event;
no treatment);
At age four, appendectomy (no complications);
At age 32, saphenectomy (no complications);
Menorrhagia (no treatment);
Implantology surgery
(antifibrinolytic treatment);
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Table 1. Cont.
Patient Origin Present Age(Years) Sex FV:C (%) FV:Ag (%)
Main Hemorrhagic
Manifestations/Challenges
P3 Italy 73 F 5 n.a.
Menorrhagia (no treatment);
Tooth extractions performed under
prophylactic treatment, but still resulting
in bleeding;
Two pregnancies (no complications);
At age 49, polyp removal from vocal cord
(antifibrinolytic treatment);
At age 56, polyp removal from uterus (under
prophylactic treatment with FFP);
At age 59, dilation and curettage procedure
(under prophylactic treatment with FFP)
P4 Iran n.a. F 4 n.a. n.a.
FV:C, functional FV activity; FV:Ag, antigen FV level (normal ranges: 58% to 140% and 64% to 139% for FV:C and
FV:Ag, respectively); F, female; n.a., not available; FFP, fresh-frozen plasma.
2.2. Identification of Molecular Defects
The mutational screening was performed by conventional Sanger sequencing on PCR-amplified
genomic fragments covering the whole F5 coding region, splice sites, and ~300 bp of the promoter region.
We disclosed a total of seven different variants, two of which (c.158+1G>A and c.5789G>
A/p.G1902D) were recurring in two subjects (Table 2) and previously reported in an Italian patient
with severe FV deficiency [24]. These two variants were indeed described as part of a unique complex
allele, but no functional studies were undertaken to dissect their actual contribution to the disease.
Of note, the c.5789G>A/p.G1902D variant involves the first nucleotide of exon 20, hence possibly
impacting on F5 splicing.
As for the remaining five novel variants, we identified one putative missense substitution,
three splicing defects (two of which are in adjacent positions in intron 19), and an additional
missense variant (c.6528G>C/p.K2148N) falling in the last nucleotide of exon 24, thus again potentially
influencing the F5 pre-mRNA splicing process (Table 2).
The identified mutations are either absent or reported in the Genome Aggregation database
(GnomAD; http://gnomad.broadinstitute.org/) at an extremely low frequency in the general
population (highest frequency was 1.42 × 10−5 for the c.5789G>A/p.G1902D variant, in which this
allele was reported four times over a total of 281,772 alleles) (Table 2).
Table 2. Genetic data of the FV-deficient patients.
Patient Exon/Intron Type of Mutation cDNA Level * NativeProtein
Mature
Protein Status Gnom AD ** Reference
P1
In1
Ex20
Ex24
Splicing
Missense or splicing?
Missense or splicing?
{
c.158+ 1G > A
c.5789G > A
c.6528G>C
-
p.G1930D
p.K2176N
-
p.G1902D
p.K2148N
Hetero
Hetero
Hetero
-
4
-
[24]
[24]
Novel
P2 In1Ex20
Splicing
Missense or splicing?
{
c.158+ 1G > A
c.5789G > A
-
p.G1930D
-
p.G1902D
Hetero
Hetero
-
4
[24]
[24]
P3
Ex15
In19
In19
Missense
Splicing
Splicing
c.5090A>G{
c.5789− 11C > A
c.5789− 12C > A
p.D1697G
-
-
p.D1669G
-
-
Hetero
Hetero
Hetero
-
1
1
Novel
Novel
Novel
P4 In19 Splicing c.5789-5T>G - - Homo *** 2 Novel
* Numbering starting from the ATG start codon according to RefSeq ENST00000367797.3. ** Number of reported
alleles in the GnomAD database (http://gnomad.broadinstitute.org/; if present, the variant was always described
in the heterozygous state). *** The mutation is considered to be present in the homozygous state, since the patient’s
parents are consanguineous (unknown degree); however, we cannot rule out the possible presence of a large deletion
that went undetected during the PCR/direct sequencing strategy used for mutation screening. Curly braces join
the two variants characterizing a previously described complex allele [24]. The square bracket joins two adjacent
variants that are present in cis in our patient. For missense mutation, the one-letter code annotation was adopted.
In, intron; Ex, exon; Hetero, variant found in the heterozygous state; Homo, variant found in the homozygous state.
2.3. In Silico Analyses of the Identified Variants
All of the identified variants were submitted to computer-assisted analyses in order to predict
their possible impact either on the F5 pre-mRNA splicing, or on the FV protein structure. In particular,
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we accomplished splice-site predictions using four online tools on the six identified putative splicing
variants; in addition, we used five algorithms for estimating the disruptive potential of the three
missense substitutions (the “genuine” p.D1669G missense variant, plus the two “elusive” variants,
c.5789G>A/p.G1902D and c.6528G>C/p.K2148N, both potentially interfering with the splicing process)
(Table 2). A summary of the in silico prediction analyses is reported in Table 3.
Table 3. In silico predictions of the identified genetic variants.
Variant
Splice-Site Predictions Missense-Variant Predictions
HSF NetGene2 SSPNN ADA SIFT HumVar HumDiv MutationTaster LRT
c.158+1G>A 60.20(87.03)
disrupted
(0.82)
disrupted
(1.00) 0.99 n.p. n.p. n.p. n.p. n.p.
c.5789G>A/p.G1902D 75.80(79.96)
0.27
(0.53)
0.61
(0.92) 0.98 ND ND ND D ND
c.6528G>C/p.K2148N 65.59(76.61)
disrupted
(0.00)
disrupted
(0.68) 0.99 D D D D D
p.D1669G n.p. n.p. n.p. n.p. ND D D D D
c.5789-11C>A 61.63(68.5)
0.30
(0.53)
0.86
(0.92) 4.97E-04 n.p. n.p. n.p. n.p. n.p.
c.5789-12C>A 64.25(68.5)
0.33
(0.53)
0.77
(0.92) 0.0078 n.p. n.p. n.p. n.p. n.p.
c.5789-5T>G 76.33(79.96)
disrupted
(0.53)
disrupted
(0.92) 0.45 n.p. n.p. n.p. n.p. n.p.
The programs used for splice-site predictions were: Human Splicing Finder (HSF), NetGene2, Splice Site Prediction
by Neural Network (SSPNN), and Adaptive Boosting algorithm (ADA). For splice-site prediction using HSF,
signals above 65 are considered strong splice sites. If the wild-type score (WT; indicated in parenthesis) is above
the threshold, and the score variation between the WT and mutant sequence is higher than 10%, the mutation
is considered to break the splice site. For NetGene2 and SSPNN, higher scores imply a higher confidence of
true splice sites. As for ADA predictions, scores above 0.7 were used to define a variant as splice altering. The
programs used for missense–variant predictions were: SIFT, PolyPhen2 (two algorithms: HumVar and HumDiv),
MutationTaster, and the likelihood ratio test (LRT), which were all enclosed in the Variant Effect Predictor (VEP)
online tool. D: damaging; ND: not damaging; n.p., not performed.
As for the putative splicing defects, the prediction tools consistently recognized a significant
difference between the wild-type and the mutant sequence only for the c.158+1G>A mutation, as well
as for the two c.5789G>A/p.G1902D and c.6528G>C/p.K2148N variants, thus supporting their possible
impact on mRNA splicing.
As for putative missense mutations, at least four (out of five) prediction programs consistently
attributed a disruptive potential to the p.D1669G and c.6528G>C/p.K2148N variants. Conversely,
the c.5789G>A/p.G1902D substitution was considered as not damaging by all five algorithms.
To give further insights on the possible pathogenic role of the amino-acid substitutions, we also
carried out: (i) a sequence conservation analysis (Figure 1a), by performing multiple alignments of
coagulation FV sequences from several vertebrates in the regions harboring the identified variants;
and (ii) a molecular modeling analysis (Figure 1b), using, as a template, the atomic coordinates
of the structure of the activated protein-C inactivated bovine FVa (FVai), i.e., the sole available in
the databases reporting the reconstruction of a complete molecular model for FV [25]. The first
analysis evidenced that the p.D1669G variant is the only non-conservative amino acid substitution,
involving a perfectly conserved residue; the mutation would introduce a small nonpolar amino
acid (glycine) in a highly polar and conserved context (the consensus sequence of the region for
the analyzed species is K/Q–E/Q–D–N/D, in which the third amino acid of this stretch is the one
involved in the identified mutation; Figure 1a). These results, together with the above-mentioned
outputs of prediction programs, strongly support the possible pathogenic role of the p.D1669G variant.
Unfortunately, it was not possible to further investigate this variant by inspecting its position within
the FVai three-dimensional structure, because this model lacks the parts of the FV molecule that
are lost during the activation/inactivation processes. Concerning instead the c.5789G>A/p.G1902D
and c.6528G>C/p.K2148N variants, both involve a residue that is part of a connecting unstructured
loop, which is exposed on the protein surface (of the C1 and C2 domain, respectively; Figure 1b).
The predicted substitutions would cause a change in the electrostatic signature of the relevant region,
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although the introduction of a charged/polar amino acid in a region exposed to the solvent could be
in theory well tolerated.
1 
 
 Figure 1. In silico charaterization of the putative missense mutations. (a) Multiple alignments of
regions of coagulation FV that are 50 amino acids long from several vertebrates harboring the three
identified missense variants. Protein sequences were obtained from the UniProt database (https:
//www.uniprot.org/) under the accession numbers P12259 (human, Homo sapiens), Q28107 (bovin,
Bos taurus), O88783 (mouse, Mus musculus), Q9GLP1 (pig, Sus scrofa), Q593B6 (psete, Pseudonaja textilis),
F1PN98 (canlf, Canis lupus familiaris), W5PKA9 (sheep, Ovis aries), H2QZV8 (pantr, Pan troglodytes),
Q90X47 (danre, Danio rerio), and K9J7M8 (xentr, Xenopus tropicalis). Residues are numbered, including
the signal peptide. Conserved amino acids are indicated by asterisks (perfect identity among species),
colons (high conservation), and dots (low conservation). Hydrophobic residues are shaded in violet.
The three identified missense variants are indicated by arrows and according to their native and
mature protein numbering. (b) Ribbon diagrams of the secondary and tertiary structures of the bovine
inactive FVa (FVai) are shown. The positions of two out of three putative missense mutations are
indicated in pink (the region harboring the p.D1669G variant is not included in the FVai structure).
Mutation numbering refers to the highly homologous human structure. The color code indicates
the different FVai domains (shades of yellow and red point to the C1 and C2 domains, respectively).
The amino-termini (N) and carboxy-termini (C) of the entire structure are also indicated.
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2.4. Molecular Characterization of Splicing Mutations
Since in silico analyses were partially inconclusive, we decided to study the possible effects of
all six putative splicing defects on F5 splicing by an ex vivo approach. To this end, appropriate F5
minigene constructs were generated, either in the wild-type form, or containing the relevant genetic
defect (for details, see Materials and Methods; Figure 2). As a first result, this cloning strategy allowed
us to verify that the c.5789-11C>A and c.5789-12C>A mutations are actually in cis, and were hence
further characterized together.
All of the minigene constructs were transiently transfected into HeLa cells, and F5 transcripts
were examined by appropriate RT-PCR assays, followed by the sequencing of all the amplified
products. This approach allowed us to demonstrate that all the investigated variants are indeed
“true” splicing defects, including the “apparent” missense c.5789G>A/p.G1902D and c.6528G>C/
p.K2148N substitutions.
In particular, three mutations (c.5789G>A/p.G1902D, c.5789-5T>G, and c.5789-11C>A/
c.5789-12C>A) were associated with the inactivation of the physiologic splice site, thus resulting
in the skipping of the corresponding exon (which was exon 20 in all cases). The skipping was total in
the case of the c.5789-5T>G mutation (Figure 2c), whereas a detectable amount of residual wild-type
splicing was associated with the c.5789G>A/p.G1902D and c.5789-11C>A/c.5789-12C>A mutations
(Figure 2b,d).
As for the c.158+1G>A defect, the mutation was responsible for the disruption of the exon 1 donor
splice site, with the concomitant activation of two cryptic splice sites (respectively located 9 and
107 nucleotides downstream of the physiologic one). The activation of these intronic splice sites was
associated with the production of two aberrant transcripts, which were both characterized by the
presence of a longer exon 1 (due to the retention of nine or 107 intronic nucleotides; see Figure 2a).
Regarding the c.6528G>C/p.K2148N mutation, this substitution was demonstrated to inactivate
the physiologic donor splice site of exon 24, with the simultaneous activation of an upstream cryptic
site, which was located within exon 24. This event was associated with the expression of a shorter F5
transcript, which was characterized by a partial skipping (85 nucleotides) of exon 24 (Figure 2e).
The identified aberrant transcripts are predicted to determine the introduction of a premature
termination codon (PTC), and hence trigger the mechanism of the nonsense-mediated mRNA decay.
This process specifically recognizes PTC-containing transcripts, thus targeting them to degradation [26],
and was previously shown to be active in the control of the post-transcriptional regulation of F5 [18].
The only exception is represented by the transcript characterized by the in-frame retention of nine
nucleotides of intron 1 (due to the mutation c.158+1G> A; Figure 2a), which however seems to be
produced at extremely low levels.
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cells transfected with the minigene constructs, separated on an agarose gel. M: molecular weight 
marker (pUC9/HaeIII); wt: RT-PCR product derived from transfected HeLa cells expressing the 
wild-type minigene; mut: RT-PCR product derived from transfected HeLa cells expressing the 
mutant construct. Right panels: Electropherograms showing the sequences of aberrant splicing 
events resulting from the analyzed mutations. 
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Figure 2. Functional characterization of the identified splicing mutations. (a–e) In each subgraph,
the molecular characterization of a putative splicing mutation is reported (the name is indicated above
the relevant panel). Left panels: Schematic representation of the F5 regions cloned into expression
vectors (either pTARGET or the pBS-KS chimeric construct). Exons are numbered and indicated by
boxes, introns are represented by lines; exons and introns are not to scale. The approximate position of
the mutation is indicated by a star. Middle panels: RT-PCR products obtained from the RNA of cells
transfected with the minigene constructs, separated on an agarose gel. M: molecular weight marker
(pUC9/HaeIII); wt: RT-PCR product derived from transfected HeLa cells expressing the wild-type
minigene; mut: RT-PCR product derived from transfected HeLa cells expressing the mutant construct.
Right panels: Electropherograms showing the sequences of aberrant splicing events resulting from the
analyzed mutations.
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3. Discussion
In this work, we investigated four patients—three Italians and one from Iran—who were affected
by mild or severe FV deficiency. We identified a total of seven different and potentially disease-causing
variants; however, understanding which among these defects were the actual mutations causing the
deficiency was the most challenging task. Indeed, we experienced some unusual occurrences:
(1) We found a complex allele composed of a putative splicing defect (c.158+1G>A) and a missense
variant (c.5789G>A/p.G1902D) in two unrelated subjects (P1 and P2). This allele was already
described in the literature, but none of the putative mutations were functionally investigated [24];
(2) We identified two missense variants, one involving the first nucleotide (the above-mentioned
c.5789G>A/p.G1902D) and the other involving the last nucleotide (c.6528G>C/p.K2148N) of the
corresponding exon, hence both potentially interfering with the pre-mRNA splicing;
(3) We disclosed two adjacent nucleotide substitutions in the heterozygous state, in theory
contributing to FV deficiency either in cis or in trans.
In order to clarify the actual contribution of all the identified putative splicing defects, it was
hence necessary to tackle their in-depth functional characterization. The molecular study was based
on expression experiments of ad-hoc minigene constructs, also to overcome the impossibility of
having access to suitable specimens from the patients. With our ex-vivo approach, we were able to
demonstrate that:
(1) Both mutations described by Bafunno et al. [24] can be regarded as splicing mutations. Since these
two mutations are present in cis on the same allele, it is plausible that their combined effect can
be considered a complete loss of function. It is worth noting that should a recombination event
involve this allele, it would be responsible for the spreading of two different mutations: one
severe (c.158+1G>A), and the other characterized by a milder effect, as we demonstrated that the
c.5789G>A defect is associated with a certain degree of wild-type splicing (Figure 2);
(2) Similar to the c.5789G>A/p.G1902D mutation, the c.6528G>C/p.K2148N defect should also be
regarded as a splicing rather than a missense mutation;
(3) The two adjacent mutations, c.5789-11C>A and c.5789-12C>A, are present in cis on the same allele,
both possibly contributing to the splicing defect. Hence, we propose the c.5789-11_12CC>AA
name for this mutation. Indeed, even though the two variants are reported as single alleles in
the GnomAD database, inspection of the relevant sequencing reads (accessible from the same
website) confirmed the phase of the two variants.
Altogether, our data allowed the identification of a total of four novel mutations (one missense,
three splicings), bringing the total number of genetic defects that have been reported to cause mild or
severe forms of FV deficiency to 138 (HGMD; database accessed 20 December 2018). Their frequency
distribution according to mutation types is depicted in Figure 3a; in this figure, we also reported on
and projected the exon–intron structure of the gene, including all of the known splicing mutations
causing FV deficiency (a total of 18 genetic defects).
In the light of what we experienced in the present work, it clearly emerges that in the
absence of experimental validations, the interpretation of the sequence variants found in genetic
screenings still represents a great challenge for the diagnosis of inherited diseases, especially in the
case of non-obvious mutations (e.g., missense variants and splicing mutations lying outside the
ultra-conserved intronic dinucleotide of the splice sites). Actually, at least two additional missense
substitutions causing FV deficiency were revealed to be splicing defects: (i) the p.Gln509His mutation,
which is an apparent missense activating a cryptic donor splice site [14]; and (ii) the p.Ala1779Thr
substitution, which interferes with intron 16 splicing [12]. Hence, four out of 18 splicing defects causing
FV deficiency (22%) have been or could have been misinterpreted as missense mutations.
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Figure 3. Mutational spectrum of FV deficiency. (a) The pie chart shows the distribution of the different
types of mutations identified in the F5 gene. Data were retrieved from the Human Gene Mutation
Database (HGMD) database (public version) with some minor amendments: (i) two of the listed
splicing defects are erroneously reported by the HGMD, and were not included in the figure; (ii)
the missense mutation reported by Bafunno et al. [24] has been counted among the splicing defects.
The chart also includes the four mutations identified in this work. (b) The mutational spectrum of
the F5 g ne exclusively refers to the splicing defects. A l of the known causative mutations for FV
deficiency are projected on the exon–intron structure of F5 on the left side of the sc me (data re ri ved
from the literature), whereas the putative splicing defects extracted from the GnomAD database are
reported on the right (with the RefSeq indication, if available). Exons are represented by boxes; introns
are represented by lines (not to scale). The FV domain structure is also indicated. Missense mutations
affecting the first/last nucleotide of the exon are indicated by a black dot beside the name; the mutations
functionally characterized in this work are bolded and underlined.
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To have a global picture of the burden of the potentially deleterious splicing defects characterizing
the F5 gene, we performed a systematic search in exome/genome data from ~140,000 individuals
belonging to the GnomAD database. Figure 3b reports all of the identified splicing variants (mapping
at intronic positions −3/−1 and +3/+6) together with all the missense defects or synonymous
variants falling in the first/last nucleotide of an exon, thus possibly interfering with the splicing
process. In this search, we only considered high-quality variants, with minor allele frequencies <0.0001,
and showing an ADA score >0.7 in prediction analyses (i.e., a score denoting potentially disruptive
mutations; see the legend in Table 3). These stringent criteria, which already have been adopted in the
literature for prevalence calculations of RICDs [27,28], allowed the identification of 11 putative splicing
defects, including the already described p.Ala1807Thr mutation; however, no functional studies were
performed to discern between the possible impact of this mutation either on the protein or on the
transcript splicing [20]. Indeed, our in silico analysis indicates that a great proportion of splicing
defects (54.5%) could be due to misinterpreted missense/synonymous variants. However, these data
should be interpreted with caution, due to the lack of a proper functional characterization.
Besides the evident benefits from the diagnostic point of view, knowledge on the actual molecular
mechanism underlying FV deficiency—and more in general, RICDs—may have further consequences
on their management and therapy. In fact, considering that splicing defects often lead to the
introduction of PTCs, the precise discernment between true null alleles and mutations that lead
to single amino-acid substitutions could be of help for predicting (and managing) the development of
inhibitors [10,29]. In addition, the knowledge of the actual splicing defect underlying the coagulation
deficiency is the fundamental prerequisite for next-generation RNA-based therapeutic approaches [30].
These are considered possible new frontiers in the treatment of RICDs, since they would allow the
restoration of the altered transcript, overcoming both the drawbacks that are typical of conventional
gene therapy (e.g., tissue specificity, correct regulation of expression, the need to deliver the transgene),
and possibly those deriving from the replacement therapy [30]. A final consideration pertains to
an old “open question” regarding the characterization of RICDs, i.e., the lack of clear correlations
between molecular defects and their associated phenotypes [8]. In fact, considering the well-known
interindividual differences in expression levels and/or in the functionality of factors responsible for
the splicing process and its regulation [31], these dissimilarities could explain the variable clinical
manifestations among deficient patients, at least for those individuals carrying splicing mutations.
4. Materials and Methods
4.1. Materials
Oligonucleotides were purchased from Sigma (St Louis, MO, USA). They were used in sequencing,
cloning, and splicing assay (see below) experiments, and their sequence is available on request.
The pTARGET vector was purchased from Promega (Madison, WI, USA). The α-globin-fibronectin
hybrid vector (modified pBS-KS) [32] was a kind gift of Dr. Emanuele Buratti (International Centre for
Genetic Engineering and Biotechnology, Trieste, Italy).
4.2. Coagulation Tests
FV activity and antigen plasma levels were measured as detailed in [33]. Briefly, FV functional
assay was based on the prothrombin time; antigen levels were evaluated by using a sandwich enzyme
immunoassay, based on a sheep anti-human polyclonal antibody (Affinity Biologicals, Hamilton, ON,
Canada). In both tests, FV levels were expressed as percentage of a control plasma mixture (pooling
together plasma from 40 normal individuals), set as 100%. Normal ranges for FV:C and antigen FV:Ag
levels were 58–140% and 64–139%, respectively. The sensitivity of the functional and immunologic
tests was 1% and 0.01%, respectively.
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4.3. DNA Extraction, PCR Amplifications, and Sequencing
Genomic DNA was extracted from whole blood using an automated DNA extractor (Chemagic
Star workstation; Hamilton, ON, Canada) and PCR-amplified under standard conditions, using primer
couples designed on the basis of known sequence of the F5 gene (RefSeq NM_000130). Direct Sanger
sequencing of purified PCR products was performed on both strands (using the BigDye Terminator
Cycle Sequencing Ready Reaction Kit v1.1; Thermo Fisher Scientific, Waltham, MA, USA) and analyzed
on an ABI-3130XL Genetic Analyzer (Thermo Fisher Scientific). The Variant Reporter program (Thermo
Fisher Scientific) was used for mutation detection. Sequencing primers were the same as in the
amplification reactions, except those used for the 2820-bp-long exon 13, which was sequenced using
additional internal primers.
4.4. In-Silico Analyses of Splice-Site and Missense Variants
Computer-assisted analysis for splice-site variants was accomplished by using four prediction
tools: Human Splicing Finder [34], NetGene2 [35], Splice Site Prediction by Neural Network [36],
and ADA [37].
Missense variants were analyzed by using five prediction programs: SIFT [38], PolyPhen2 (two
algorithms) [39], MutationTaster [40], and Likelihood Ratio Test (LRT) [41]. These five programs,
together with the ADA tool, were run through the Variant Effect Predictor (VEP) online tool maintained
in the Ensembl resource (https://www.ensembl.org/info/docs/tools/vep/index.html) (access on
8 January 2019), which takes advantage of the dbNSFP v3.0 databases [42].
Multiple alignments of the FV protein from several vertebrates in the regions surrounding the
identified mutations were performed by retrieving FV protein sequences from the UniProt database
(https://www.uniprot.org/) (access on 16 December 2018), and by producing the alignment with the
CLUSTAL Omega (version 1.2.4) software [43]. Ribbon diagrams of the bovine FVai were produced
using the Swiss-Pdb Viewer 4.1 software [44] and the Protein Data Bank 1SDD entry [25].
4.5. Mini-Gene Construction
Two F5 regions (from exon 1 to intron 2, and from intron 18 to intron 21) were PCR amplified from
the genomic DNA of the combined heterozygous patient P1, using the Expand 20 KbPLUS PCR System
(Roche, Basel, Switzerland) according to the manufacturer’s instructions. PCR products were inserted
into the pTARGET vector using the pTARGET Mammalian Expression T-Vector System Kit (Promega).
This strategy allowed the production of four plasmids, two wild-type for the above-mentioned F5
regions, and the other two carrying either the c.158+1G>A or the c.5789G>A mutation. The c.5789-5T>G
mutation was instead introduced in the wild-type construct spanning the intron 18-intron 21 region,
by the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), according to the
manufacturer’s instructions. As for the c.6528G>C mutation, we took advantage of the pTARGET-based,
wild-type plasmid covering the intron 22-exon 25 region, already described by our group [18]. In this
case, the relevant mutation was again introduced by the QuickChange Site-Directed Mutagenesis Kit.
As for the c.5789-11C>A and c.5789-12C>A mutations, for which we had to understand if they
were in cis or in trans in patient P3, we PCR amplified a F5 genomic region (covering exon 20 and its
adjacent intronic regions) from the genomic DNA of the patient. PCR products were inserted into the
α-globin-fibronectin hybrid vector. This approach revealed that the c.5789-11C>A and c.5789-12C>A
mutations are actually in cis, and allowed the production of the corresponding wild-type construct.
All plasmids were isolated by the PureYield Plasmid Midiprep System (Promega) and were
checked by sequencing.
4.6. Cell Cultures, Transfections, and Splicing Assays
Human cervix carcinoma HeLa cells were cultured in Dulbecco’s modified Eagle’s Medium
(DMEM), supplemented with fetal bovine serum (10%), glutamine (1%), and antibiotics (100 IU/mL
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penicillin, 100 µg/mL streptomycin). Cells were grown at 37 ◦C in a humidified atmosphere of 5%
CO2 and 95% air and cultured according to standard procedures. All reagents for cell cultures were
from EuroClone (Wetherby, UK).
HeLa cells were seeded in six-well plates at a density of 2.5 × 105/well; 24 h later, transfections
were performed using either the wild-type or each of the mutant vector. As a negative control, cells were
transfected with the relevant empty plasmid (the pTARGET plasmid, or the α-globin-fibronectin hybrid
vector). For each experiment, 4 µg of DNA were transfected using the Fugene reagent (Promega).
After 24 h, the medium was removed, cells washed, and RNA was extracted using the Eurozol
reagent (EuroClone).
First strand cDNA synthesis, starting from 500 ng of total RNA, was performed using random
hexamers and the ImProm-III Reverse Transcriptase (Promega) in a final volume of 20 µL. One µL was
used as template for the following PCR amplification, with primers mapping in the upstream and
downstream exonic regions of the exon involved in the mutation. Amplified and purified RT-PCR
fragments were analyzed by Sanger sequencing, as described above.
All individuals participating to the present study gave their informed consent before blood
withdrawal, in accordance with the local Ethics Committees and with the ethical principles of the
Helsinki Doctrine.
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DMEM Dulbecco’s modified Eagle’s Medium
F5 Coagulation factor V gene
FV Factor V
FVa Activated factor V
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FVai Activated protein-C inactivated FVa
FV:C Factor V coagulant activity
FXa Activated factor X
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